Azithromycin + Moxifloxacin

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Bacterial Infections

Conditions

Bacterial Infections, Eye Infections

Trial Timeline

Dec 1, 2007 → —

About Azithromycin + Moxifloxacin

Azithromycin + Moxifloxacin is a approved stage product being developed by Merck for Bacterial Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00564447. Target conditions include Bacterial Infections, Eye Infections.

What happened to similar drugs?

4 of 20 similar drugs in Bacterial Infections were approved

Approved (4) Terminated (2) Active (15)
🔄DoripenemJohnson & JohnsonPhase 3
🔄levofloxacinJohnson & JohnsonPhase 3
🔄doripenemJohnson & JohnsonPhase 3
🔄AzaSite + TobramycinMerckPhase 3
🔄AzaSiteMerckPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00564447ApprovedCompleted

Competing Products

20 competing products in Bacterial Infections

See all competitors